drugset / Trial / NCT00833560
A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of bortezomib in combination with a standard regimen of cyclophosphamide and dexamethasone.
Timeline
- Start
- 2006-03
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 900 mg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 1500 mg | Intravenous |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |